Cost-effectiveness of romosozumab for the treatment of postmenopausal women at very high risk of fracture in Canada
Summary: This study evaluated the cost-effectiveness of 1 year of romosozumab followed by alendronate versus oral bisphosphonates alone in women with postmenopausal osteoporosis at very high risk for fracture in Canada. Results showed that romosozumab sequenced to alendronate is a cost-effective tre...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Springer Science and Business Media Deutschland GmbH
2022
|
| Subjects: | |
| Online Access: | View Fulltext in Publisher |